^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ABBV-184
i
Other names: ABBV-184, ABBV184, ABBV 184
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AbbVie
Drug class:
CD3 agonist, Survivin inhibitor
Related drugs:
6ms
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell Receptor/Anti-CD3 bispecific protein, in adults with Previously treated AML or NSCLC. (PubMed, Expert Rev Anticancer Ther)
ABBV-184 was well tolerated and demonstrated preliminary evidence of CD3 engagement with transient cytokine increases and peripheral lymphocyte decreases. NCT04272203.
P1 data • Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
ABBV-184
over1year
ABBV-184: A novel survivin-specific TCR/CD3 bispecific T cell engager is active against both solid tumor and hematological malignancies. (PubMed, Mol Cancer Ther)
Consistent with the expression profile of survivin across a broad range of both hematological and solid tumors, treatment of AML and NSCLC cell lines with ABBV-184 results in T cell activation, proliferation, and potent redirected cytotoxicity of HLA-A2 positive target cell lines, both in vitro and in vivo, including patient-derived AML samples. These results indicate that ABBV-184 is an attractive clinical candidate for the treatment of patients with AML and NSCLC.
Journal • IO biomarker
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • HLA-A2 positive
|
ABBV-184
Share via
